SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

Saegis Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: SGS742

Study type: Interventional

Funder types: Industry

Identifiers

NCT00093951

IA0061

Details and patient eligibility

About

The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.

Full description

SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.

Sex: All

Ages: 55 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 55 to 90 years of age
• Diagnosed with mild to moderate Alzheimer's disease
• Willing caregiver
• In general good health

Exclusion criteria

• Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.

Prohibited Meds:

• Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)